Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 6 APIs Including Inebilizumab Designated as Orphan Drugs: MHLW
February 19, 2020
- Authorized Generics for Memary, Celecox among Approval List towards June Listing
February 18, 2020
- MHLW Panel to Review Nippon Shinyaku’s Oligonucleotide DMD Drug, Latuda and More on Feb. 28
February 18, 2020
- Japan OKs Edirol Generics towards June Listing, First Gx Entries for 13 Other Drugs Too
February 17, 2020
- Zolgensma Up for Japan Advisory Panel Meeting on Feb. 26, Listing Expected as Early as May
February 17, 2020
- MHLW to Weigh All-Year Invitation for Sakigake Requests: Top Pharmacy Officer
February 14, 2020
- Council Backs Public Knowledge-Based Application for Additional Indication for Novartis’ Sandostatin
February 14, 2020
- Enhertu, BNCT, Tepotinib and More Up for MHLW Panel Review; March Approval Eyed
February 13, 2020
- MHLW Calls for Stable Supplies of HIV Drugs amid Coronavirus Outbreak
February 13, 2020
- PMDA to Set Up New Consultation Services for Continuous Manufacturing, Database Use
February 12, 2020
- MHLW Urges Pharmacies to Limit Per-Customer Purchases for Face Masks, Sanitizer
February 12, 2020
- Chuikyo Issues Recommendation for 2020 Reimbursement Reform; Biosimilar Premium Set at 1,500 Yen per Month
February 10, 2020
- Chuikyo OKs Supplementary Opinions for 2020 Reimbursement Reform; No Mention on Health Coverage Review
February 6, 2020
- AMED to Share Research Data to Tackle Wuhan Coronavirus
February 4, 2020
- Chuikyo’s Draft Supplementary Opinions for 2020 Reimbursement Reform Calls for Medical Validity, Cost-Effective Analysis for Prescriptions
February 3, 2020
- Takeda’s RCC Drug Cabometyx Now in Line for March Approval; Alecensa, Rozlytrek Opdivo and More
January 30, 2020
- MHLW to Incentivize Physicians to Use Biosimilars with New Premium
January 30, 2020
- Sanofi to Temporarily Stop Taking Orders for ActHIB due to “Multiple Cases” of Rust Found in Needles: MHLW
January 30, 2020
- Japan Ups Responses against Wuhan Coronavirus as First Domestic Transmission Confirmed
January 29, 2020
- MHLW Panel Gives Thumbs Up for Novartis’ ADM Med Brolucizumab for Approval in as Early as March
January 29, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…